Sigma Granted Patent for REDTaq™ DNA Polymerase Product Line
News Sep 16, 2005
Sigma, a division of Sigma- Aldrich Corporation has announced that the U.S. Patent and Trademark Office granted the Company U.S. Patent Number 6,942,964, entitled "Tracer Reagents that Enhance Reaction-Product Analysis," covering the array of direct-load RED enzymes already being offered in Sigma's PCR product line.
REDTaq™ products are a blend of various DNA polymerases combined with an inert red dye. The dye allows quick visual confirmation of enzyme addition and reaction homogeneity.
The sample can also be loaded directly onto an agarose gel for electrophoresis following PCR. The red dye has no effect on downstream applications.
"Our RED enzymes have been successful as an added convenience and time-saver to the research community," said Keith Jolliff, Director of Strategic Marketing in the Biotechnology Business Unit at Sigma-Aldrich.
"This patent adds to our technology portfolio and expands our leadership in life sciences and high technology."
Sigma claims that, the RED enzyme product line covers all areas of PCR including routine amplification, hot start, long and accurate, and genomic DNA amplification.
The enzymes come in both a stand-alone format as well as a ReadyMix™ formula for added convenience.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.